Circulation and degradation of GIP and GLP-1

被引:221
|
作者
Deacon, CF [1 ]
机构
[1] Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark
关键词
glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; gut hormone; incretin; dipeptidyl peptidase IV; neutral endopeptidase 24.11;
D O I
10.1055/s-2004-826160
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted from the intestinal K- and L-cells, respectively, but are immediately subject to rapid degradation. GLP-1 is found in two active forms, amidated GLP-1 (7-36) amide and glycine-extended GLP-1 (7-37), while GIP exists as a single 42 amino acid peptide. The aminopeptidase, dipeptidyl peptidase IV (DPP IV), which is found in the endothelium of the local capillary bed within the intestinal wall, is important for the initial inactivation of both peptides, with GLP-1 being particularly readily degraded. DPP IV cleavage generates N-terminally truncated metabolites (GLP-1 (9-36) amide / (9-37) and GIP (3-42)), which are the major circulating forms. Subsequently, the peptides may be degraded by other enzymes and extracted in an organ-specific manner. However, other endogenous metabolites have not yet been identified, possibly because existing assays are unable either to recognize them or to differentiate them from the primary metabolites. Neutral endopeptidase 24.11 has been demonstrated to be able to degrade GLP-1 in vivo, but its relevance in GIP metabolism has not yet been established. Intact GLP-1 and GIP are inactivated during passage across the hepatic bed by DPP IV associated with the hepatocytes, and further degraded by the peripheral tissues, while the kidney is important for the final elimination of the metabolites.
引用
收藏
页码:761 / 765
页数:5
相关论文
共 50 条
  • [1] On the physiology of GIP and GLP-1
    Holst, JJ
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 747 - 754
  • [2] INCRETIN HORMONES GIP AND GLP-1
    Kieffer, Timothy James
    Fujita, Yukihiro
    Riedel, Michael
    Wideman, Rhonda
    JOURNAL OF PHYSIOLOGICAL SCIENCES, 2009, 59 : 87 - 87
  • [3] Biology of incretins: GLP-1 and GIP
    Baggio, Laurie L.
    Drucker, Daniel J.
    GASTROENTEROLOGY, 2007, 132 (06) : 2131 - 2157
  • [4] Extrapancreatic effects of GIP and GLP-1
    Vella, A
    Rizza, RA
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 830 - 836
  • [5] Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
    Mentlein, Rolf
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (04) : 443 - 452
  • [6] Degradation of GIP but not of GLP-1 is reduced after protein ingestion in obese subjects
    Lindgren, O.
    Vikman, J.
    Deacon, C. F.
    Carr, R. D.
    Holst, J. J.
    Ahren, B.
    DIABETOLOGIA, 2010, 53
  • [8] Immunoassays for the incretin hormones GIP and GLP-1
    Deacon, Carolyn F.
    Holst, Jens J.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (04) : 425 - 432
  • [9] Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
    Liu, Qiyuan Keith
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [10] GLP-1 and GIP receptors co-agonists
    Bernard, Elise S. C.
    Metcalfe, Jacky
    Sermadiras, Isabelle
    Collinson, Andie
    Naylor, Jacqueline
    Hornigold, David
    Bednarek, Maria A.
    JOURNAL OF PEPTIDE SCIENCE, 2018, 24 : S143 - S143